피디에스 바이오테크놀로지(PDSB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.23 (-1.11%), 시가총액 $0.06B, 52주 범위 $0.54 ~ $1.79.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and l
피디에스 바이오테크놀로지의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
피디에스 바이오테크놀로지의 현재 주가는 $0.23 (-1.11%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
피디에스 바이오테크놀로지의 시가총액은 약 $0.06B입니다.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS010